68W-28963-06951
3 vaccinations
3 coded responses
26 check-ins
3 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 100 / NY
- Registered
- 2020-12-23
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-23
Registered in v-safe
-
2020-12-23
Dose 1 — Pfizer-BioNTech
- 2020-12-23
- 2020-12-24
- 2020-12-26
- 2020-12-27
-
2020-12-28
Health check-in — days 1–6 daily, dose 1Feeling: Good · Rash, not including the immediate area around the injection siteAdult check-in
-
2020-12-29
Health check-in — days 1–6 daily, dose 1Feeling: Good · Rash, not including the immediate area around the injection siteAdult check-in
- 2020-12-30
- 2021-01-06
-
2021-01-11
Dose 2 — Pfizer-BioNTech
-
2021-01-15
Survey response — days 1–6 daily, dose 2MedDRA: Unevaluable event — Feeling: Good · Site: Pain · Rash, not including the immediate area around the injection siteFree text: StomachMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-16
Survey response — days 1–6 daily, dose 2MedDRA: Urticaria — Feeling: Good · Rash, not including the immediate area around the injection siteFree text: HivesMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-20
Health check-in — day 7, dose 2Feeling: Good · Rash, not including the immediate area around the injection site · Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationAdult check-in
-
2021-01-20
Report sent to call center — day 7, dose 2Get care from a doctor or other healthcare professional1 call case(s)
-
2021-01-25
Survey response — day 14, dose 2MedDRA: Skin lesion — Feeling: Good · Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Diagnosed with pityriasis rosea by PCP. First lesion appeared after first vaccination 12/23, diffuse trunk lesions appeared after second dose 1/11MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-25
Report sent to call center — day 14, dose 2Get care from a doctor or other healthcare professional1 call case(s)
- 2021-02-01
- 2021-02-08
- 2021-02-15
- 2021-02-22
-
2021-03-25
Call successfulParticipant prefers to complete VAERS report online
- 2021-04-12
- 2021-07-12
-
2021-12-01
Dose 3 — Pfizer-BioNTech
- 2021-12-20
- 2021-12-22
- 2021-12-29
- 2022-01-05
- 2022-01-12
- 2022-03-02
- 2022-06-01
- 2022-12-01
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-23 | Pfizer-BioNTech | |
| 2 | 2021-01-11 | Pfizer-BioNTech | |
| 3 | 2021-12-01 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-01-20 | Successful | Participant prefers to complete VAERS report online |
| 2021-01-25 | Successful 2021-03-25 |
Participant prefers to complete VAERS report online |
Free text
Release 2 — days 1–6 daily, dose 2
Systemic reaction (other): Stomach
Systemic reaction (other): Hives
Release 2 — day 14, dose 2
Symptoms: Diagnosed with pityriasis rosea by PCP. First lesion appeared after first vaccination 12/23, diffuse trunk lesions appeared after second dose 1/11
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Skin lesion | ✓ | ✓ | ✓ |
| SRO | Unevaluable event | ✓ | ✓ | ✓ |
| SRO | Urticaria | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release